Facon, T. Et Al. 2024. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. The New England journal of medicine , vol.391, no.17 , 1597-1609.

Facon, T., Dimopoulos, M., Leleu, X. P., Beksac, M., Pour, L., Hájek, R., ... Liu, Z.(2024). Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. The New England journal of medicine , vol.391, no.17, 1597-1609.

Facon, Thierry Et Al. "Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma," The New England journal of medicine , vol.391, no.17, 1597-1609, 2024

Facon, Thierry Et Al. "Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma." The New England journal of medicine , vol.391, no.17, pp.1597-1609, 2024

Facon, T. Et Al. (2024) . "Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma." The New England journal of medicine , vol.391, no.17, pp.1597-1609.

@article{article, author={Thierry Facon Et Al. }, title={Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma}, journal={The New England journal of medicine}, year=2024, pages={1597-1609} }